Teva Pharmaceutical Industries Limited filed a Form 8-K on October 29, 2026, disclosing that its Board of Directors elected Dr. David J. Brailer as a new board member, effective November 3, 2026, following a board meeting held on October 27, 2026.

Key Highlights

  • New director elected: Dr. David J. Brailer was elected to Teva's Board of Directors, effective November 3, 2026, to serve until Teva's 2027 annual meeting of shareholders.
  • Independence determination: The Board determined that Dr. Brailer qualifies as an independent director under the listing rules of the New York Stock Exchange.
  • Committee assignments: Dr. Brailer is expected to serve on the Human Resources and Compensation and Compliance Committees of the Board.
  • Current roles: Dr. Brailer has served as Chairman and Chief Executive Officer of medem.ai since 2024, and as Founder and Executive Chairman of Health Evolution since 2010.
  • Prior executive role: From 2022 to 2026, Dr. Brailer served as Chief Health Officer of The Cigna Group, and from 2024 to 2026 also as its Chief Transformation Officer.
  • Compensation: Dr. Brailer will receive the same compensation as Teva's other non-executive directors, as described in the company's definitive proxy statement filed with the SEC on March 31, 2026.

Dr. David Brailer Joins Teva Board With Health-Tech and Policy Background

According to the filing, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported that at a Board of Directors meeting held on October 27, 2026, the Board elected Dr. David J. Brailer as a director. His term begins November 3, 2026, and runs until the company's 2027 annual meeting of shareholders. The Board determined he qualifies as an independent director under New York Stock Exchange listing rules.

The filing describes Dr. Brailer's professional background in detail. In addition to his current role as Chairman and CEO of medem.ai, a health-tech company, since 2024, he is Founder and Executive Chairman of Health Evolution since 2010, and Founder and Managing Partner of Health Evolution Partners since 2007. He served as Chief Health Officer of The Cigna Group from 2022 to 2026, and concurrently as Chief Transformation Officer from 2024 to 2026. Since 2021, he has served as Vice Chairman of the Duke Margolis Health Policy Institute. He previously served on the boards of Prolacta Bioscience, Inc. from 2012 to 2023, and Walgreens Boots Alliance, Inc. from 2012 to 2021.

The filing also states that Dr. Brailer holds a Ph.D. in Management Science and Applied Economics from The Wharton School of the University of Pennsylvania, and an M.D., with honors, and a B.S., cum laude, from West Virginia University. The company disclosed that there are no arrangements or understandings between Dr. Brailer and any other persons related to his election, no direct or indirect material interest in any related party transaction requiring disclosure under Item 404(a) of Regulation S-K, and no family relationships between Dr. Brailer and any director or executive officer of the company.

What Was Disclosed

Teva disclosed the election of Dr. David J. Brailer to its Board of Directors, effective November 3, 2026, his expected committee assignments, his professional background, his independence status, and that his compensation will match that of other non-executive directors as detailed in the March 31, 2026 proxy statement.